
Eyecelerator @ AAO 2023
San Francisco Marriott Marquis | Thursday, November 2
PROGRAM AGENDA
*Panels are in development and speakers are subject to change.
Registration + Networking Breakfast
7:00 – 8:00 a.m.
Registration and breakfast
​
Welcome Remarks
8:00 – 8:10 a.m.
-
Stephen D. McLeod, MD, CEO, American Academy of Ophthalmology
-
Allen C. Ho, MD, Retina Program Director
-
Gil Kliman, MD, Program Director
S1: The Year in Review
8:10 – 8:45 a.m.
Overview and discussion of key trends and events in the 2023 ophthalmology marketplace.
​
Moderators: Gil Kliman, MD and Jim Mazzo
Market Overview: Kristen Harmon Ingenito, Market Scope
​
Public and Private Markets: Andrew Gitkin, Vice Chairman, Health Care Investment Banking, Raymond James
​
Panel:
-
Sebastien Allard, VP, Corporate Development Strategy, Alcon
-
Jay S. Duker, MD, CEO, Eyepoint Pharmaceuticals
-
Adrienne L. Graves, PhD, Former Board Chair, IvericBio
-
Wende Hutton, MBA, General Partner, Canaan Partners
​
S2: Industry’s Role in Nurturing Robust Innovation
8:45 – 9:30 a.m.
Significant financial commitments are required for FDA clearance of new products. As global strategics increasingly delay investment, how can pioneering companies persevere?
​
Moderators: Zaina Al-Mohtaseb, MD and Nicole R. Fram, MD
Panel:
-
Andrew Gitkin, Vice Chairman, Health Care Investment Banking, Raymond James
-
Kendra Hileman, Head of Instrumentation R&D, Alcon
-
Sean Ianchulev, Eyenovia
-
Philip Kowalczyk, VP, Business Development, Johnson & Johnson Vision
-
Mariam Maghribi, Chief Business Officer, Shifamed
-
Ramin Valian, VP, US Eyecare, Allergan, an AbbVie Company
Networking Break
9:30 – 10:00 a.m.
Networking Break – Marriott Grand Ballroom Foyer
S3: Mapping the Future of Geographic Atrophy
10:00 – 11:00 a.m.
With the approval of two new drugs and multiple other pathways under investigation in human trials, new treatments for GA have the potential to revolutionize patient care.
​
Moderators: Robert L. Avery, MD and Aleksandra V. Rachitskaya, MD
​
Presentations:
-
ONL Therapeutics: David Esposito, CEO
-
Annexon Biosciences: Douglas Love, Esq., President & CEO
-
Lineage Cell Therapeutics: Brian Culley, CEO
-
Aviceda Therapeutics: Mohamed A. Genead, MD, Co-Founder, CEO & President
-
Apellis: Cedric Francois, MD, CEO
-
Iveric Bio: Erin Henry, VP, Strategy & Innovation
Panel:
-
Wiley Chambers, MD, Director, Division of Ophthalmology, FDA
-
Cedric Francois, MD, CEO, Apellis
-
Erin Henry, VP, Strategy & Innovation, Iveric Bio
-
Daniel Lyons, PhD, CFA, Janus Henderson Investors
-
Namrata Saroj, OD, Principal, All Eyes Consulting
​
The Winning Pitch Challenge
11:00 – 11:45 a.m.
Back by popular demand! The Shark Tank-style competition features pitches from three early-stage ophthalmology innovators, with judges and the audience deciding who will take home cash prizes worth $45,000.
​
Moderators: Vance Thompson, MD and Robert Warner ​
Finalists:
-
Niki Bayat, PhD – AesculaTech Humidifeye
Mentor: Leonard Borrmann, PharmD -
Oussama Boundaoui, MD – Regenoptics Tamponading Hydrogel
Mentor: Shravanthi Reddy, PhD -
David Kleinman, MD – Calm Water Therapeutics, LLC
Mentor: Robert Dempsey
Judges: ​
-
Adrienne L. Graves, PhD, Former Board Chair, Iveric Bio
-
​Richard L. Lindstrom, Founder, Minnesota Eye Associates
-
Angela Macfarlane, CEO, Perceive
-
Jim Mazzo, Executive Chairman, Neurotech Pharmaceuticals
​​
Networking Lunch
11:45 a.m. – 12:30 p.m.
Enjoy a bite to eat with your colleagues.
Presenting Company Showcases
12:30 – 2:15 p.m.
Forty companies present innovative new treatments, products and services. Breakout rooms will operate simultaneously for each segment. Follow these links for showcase schedules:
​
Retina Showcase: Nob Hill Room
Anterior Segment Showcase: Salons 11 – 14
Glaucoma + Digital Showcase: Salons 3 – 5
Networking Break
2:15 – 2:45 p.m.
Networking Break
​
S4: Key Ingredients of Successful Innovation
2:45 – 3:15 p.m.
Listen and learn from strategics, start-ups and biotech investors on what it takes to successfully get ophthalmic innovations to market and efficiently improve quality of life for patients.
​
Moderators: Allen C. Ho, MD and Robert L. Avery, MD
Panel:
​​
- Anthony P. Adamis, MD, Chief Scientific Officer, EyeBio
David Bingaman, Chief Development Officer, Ora - Christoper Brittain, MBBS, Head of Global Development, Genentech
- Wiley Chambers, MD, Director, Division of Ophthalmology, FDA
- Lori-Ann Christie, PhD, Principal, Visionary Ventures
- Steve Pakola, MD, Chief Medical Officer, REGENXBIO
- Richard Small, CEO, Neurotech
- Robert Vitti, MD, Vice President, Regeneron
S5: Decoding the Viability of Artificial Intelligence
3:15 – 4:00 p.m.
Uncover the secrets of why some AI concepts spur vigorous investment while others struggle to gain traction.
​
Moderators: Julie M. Schallhorn, MD, MS and Lejla Vajzovic, MD
Keynote Speaker:
The AI Gold Rush? A Matter of Perception
Khizer R. Khaderi, MD, MPH, Director, Stanford Human Perception Lab
​
Presentations:
​
-
AI – Generative: Vivek Natarajan, AI Researcher, Google
-
AI – Screening: Kester Nahen, PhD, CEO Notal Vision
-
AI – Image Analysis: Kaushal Solanki, Eyenuk
-
AI – Big Pharma: Victor Chong, MD, Global Head of Retina, Janssen
Panel: ​
-
Victor Chong, MD, VP, Global Head of Retina, Janssen
-
Malvenia Eydelman, MD, Director, FDA
-
Ranya Habash, MD, CEO, LifeLong Viion
-
Vivek Natarajan, AI Researcher, Google
-
Kester Nahen, PhD, CEO, Notal Vision
​
S6: 10 Perspectives For Navigating Today’s Regulatory Landscape
4:00 – 4:45 p.m.
Examine the relevance of current Patient Reported Outcomes (PROs) and the feasibility of new draft guidance for retina treatments.
​
Moderator: Arsham Sheybani, MD and Charles Wykoff, MD, PhD
Panel:
-
David S. Boyer, MD, Sr Partner, Retina Vitreous Associates
-
Wiley Chambers, MD, Director, Division of Ophthalmology, FDA
-
Malvina Eydelman, MD, Director, CDFH/FDA
-
Gus Gazzard, MD, Director, Moorfields Eye Hospital
-
Chuck Hess, Global VP Commercial Development and Digital Health, Bausch + Lomb
-
Eris Jordan, OD, VP Global Clinical and Medical Affairs, Aurion Biotech
-
Gary D. Novack, PhD, President, PharmaLogic Development
-
Steven C. Schallhorn, MD, Chief Medical Officer, Zeiss
​​
Closing Bell and People's Choice Awards
4:45 – 5:00 p.m.
The program committee wraps the day with insights and People's Choice recognition.
​
-
Zaina Al-Mohtaseb, MD, Program Co-Chair
-
Robert L. Avery, MD, Program Co-Chair
-
Gil Kliman, MD, Program Director
Reception
5:00 – 6:00 p.m.
Enjoy refreshments and connect!
​